Biocorrx Inc. (BICX) Stock Price & Analysis

Biocorrx Inc. (BICX) fell 4.29% to USD 0.2 as of September 8, 2026 at 14:08 UTC, according to Nexqual real-time market data.

BICX last closed at USD 0.2; the session ranged USD 0.2–0.2 on volume of 100 shares. Market capitalization is —, with a 52-week range of USD 0.15–1.28 (OID). Source: Nexqual, September 8, 2026 at 14:08 UTC.

Key Statistics (as of September 8, 2026 at 14:08 UTC)

Technical Analysis (BICX)

Nexqual's technical model rates BICX "SELL" based on 1 bullish and 5 bearish signals across 126 daily candles, as of September 8, 2026 at 14:08 UTC.

From Biocorrx Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)

Key Strengths & Strategy (as disclosed to the SEC)

• We rely primarily on patent protection and trade secrets, as well as a combination of copyright and trademark laws and nondisclosure and confidentiality agreements to protect our technology and intellectual property rights.
• Despite our intellectual property rights practices, it may be possible for a third party to copy or otherwise obtain and use our technology without authorization, develop similar technology independently or design around our patents.   We cannot be assured that any of our pending patent applications will result in the issuance of a patent to us.
• If any of our patents fail to protect our technology, it would make it easier for our competitors to offer similar products.

Partnerships

• Research related to BICX102 and BICX104 was supported by the National Institute on Drug Abuse of the National Institutes of Health under award numbers UG3DA047925 and UH3DA047925.   BICX104 was previously being developed through a cooperative agreement with the National Institutes of Health (NIDA), part of the National Institutes of Health (NIH), under award number UH3DA047925, funded by the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative.
• Total payments made to OCRC under the agreement as of December 31, 2025 were $503,089, and there was no outstanding balance due to OCRC as of December 31, 2025 or 2024.   On October 31, 2020, the Company entered into a written management services agreement with Joseph DeSanto MD, Inc. ("Medical Corporation") under which the Company provides management and other administrative services to the Medical Corporation.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 14:08 UTC. This page is informational and not investment advice.